AzTrials
AzTrials

Stroke, AcuteBEGASTONNCT04758052

Tracheostomy With Bedside Simultaneous Gastrostomy Vs Usual Care Tracheostomy And Delayed Gastrostomy Placement

A study testing Timing of placement in people with Stroke, Acute and TBI, run by University of Mississippi Medical Center at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

There is currently no prospective study analyzing the effect of tracheostomy with bedside simultaneous gastrostomy versus tracheostomy with delayed gastrostomy placement (TSG versus TDG) on the outcomes of neurocritically-ill patients. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Stroke, Acute, TBI, Neuromuscular Diseases
What is being tested?
Timing of placement
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteUnited States
Study dates
31 Mar 2021to Aug 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18 years old- 85 years old
  • Admitted under the NSICU service
  • Shared-decision making with surrogate decision maker and primary neuro-intensivist agreement to proceed with tracheostomy and gastrostomy with documented discussion.
  • have indications for tracheostomy and gastrostomy
  • Subjects or their SDM or legally authorized representative (LARs) must voluntarily provide informed consent prior to the initiation of any study-specific procedure in a form approved by an independent IRB. In the absence of subject's ability to provide informed consent, informed consent must be given by a person who has the legal right to act on behalf of the subject in accordance with local laws.

Who cannot join

  • Patients who require tracheostomy only or gastrostomy only
  • history of prior gastrostomy, tracheostomy, laryngectomy, gastrostomy prior to tracheostomy decision, known head and neck and gastrointestinal abnormality (cancer, congenital abnormality, anatomic variants)
  • withdrawal of care, a transfer from another service or hospital if patient has been there for >24hr.
  • known social discharge issues anticipating hospital stay >100 days
  • Patients with nonsurvivable injuries, anticipated mortality <72 hours
  • standard of care contraindications for either bedside tracheostomy and gastrostomy
Show all 15Show fewer
  • Absolute contraindications for gastrostomy: gastric outlet obstruction, significant gastroparesis, significant gastroesophageal reflux, a proximal high-output entercutaneous fistula
  • Standard Contraindications for percutaneous gastrostomy technique: ascites, morbid obesity and esophageal and gastric pathology
  • Standard Contraindications for either PEG or PUG procedures
  • Standard Contraindications to percutaneous dilational tracheostomy: Gross anatomical distortion of the neck, previous neck surgery , burns, radiotherapy, unstable or rigid cervical spine, tracheal distortion, stenosis, or malacia, morbid obesity (BMI >35kg/m2), massive thyroid gland or vessels in the operation field on ultrasound, hemodynamic instability, refractory intracranial hypertension, hemodynamic instability, Coagulopathy (Aptt>50s, INR>1.5, platelet count <50,000μL, emergency need for a tracheostomy or need for a permanent tracheostoma, very difficult airway management
  • Pregnancy
  • Life expectancy less than three-weeks
  • Goals of care disagreement between care team and LAR
  • braindead
  • LAR preferred procedures placed in LTAC

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Christa O'Hana S. Nobleza

    Jackson, Mississippi, 39216

Other trials in United States

About this study

Official title: Bedside Gastrostomy With Simultaneous Tracheostomy Effect On Outcomes Of Neurocritically-Ill Patients (Proof Of Concept Study)

There is currently no prospective study analyzing the effect of tracheostomy with bedside simultaneous gastrostomy versus tracheostomy with delayed gastrostomy placement (TSG versus TDG) on the outcomes of neurocritically-ill patients. The investigators will study TSG via concomitant PDT and PUG procedures, while TDG will occur per usual care. This study is a prospective randomized open-label blinded endpoint study to assess the effect of tracheostomy with bedside simultaneous gastrostomy (TSG) versus the usual care of tracheostomy with delayed gastrostomy (TDG) placement on outcomes of neurocritically-ill patients.

Read the detailed description

The practice of performing tracheostomy and gastrostomy simultaneously has been reported since the 1980s. The safety and feasibility of simultaneous tracheostomy with gastrostomy (TSG), compared to non-simultaneous or delayed approach (TDG), among neurocritically-ill patients have been reported by various case series and retrospective cohort studies.The timing of tracheostomy generally among neurocritically-ill patients varies from early <5 days or late >7 -10 days. There are currently no guidelines specifically on neurocritically-ill patients and the timing of gastrostomy placement however, it is generally recommended to wait 2-3 weeks as a time limited trial however, there are patients that are able to leave the hospital with the main limitation as being the feeding access. Although it has been suggested to consider tracheostomy to become an indication for gastrostomy this has not been widely accepted although there is an increase in awareness of the TSG approach especially in patients with neurologic conditions.

Tracheostomy have been traditionally indicated include airway obstruction associated with infection, malignancy, injury, sleep apnea and vocal cord dysfunction, prolonged intubation, facilitate weaning from mechanical ventilation, pulmonary hygiene and aspiration.

Gastrostomy tubes have been considered as standard of care for patients requiring alternate forms of long-term enteral feeding. Other indications include long-term nutrition support associated with neurologic or spinal cord deficits, primary swallowing dysfunction, facial or pharyngeal injuries, malignancy of the head and neck and the esophagus, gastric decompression. Approaches available to perform tracheostomy include open, percutaneous tracheostomy, percutaneous dilatational tracheostomy (PDT); Percutaneous Radiologic Tracheostomy and percutaneous ultrasound tracheostomy. Gastrostomy is a temporary or permanent controlled fistula from the lumen of the stomach to the skin. For gastrostomy, approaches include open surgical gastrostomy (SG) or Stamm gastrostomy, Percutaneous endoscopic gastrostomy (PEG), Percutaneous Radiologic gastrostomy (PRG) and Percutaneous Ultrasound gastrostomy (PUG).

In a retrospective cohort study on the outcomes of neurocritically-ill patients who have undergone TSG versus delayed gastrostomy TDG (non-simultaneous tracheostomy and gastrostomy), the patients undergoing TSG had shorter Neurocritical Care Unit (NCCU) length of stay (LOS), hospital LOS, overall hospital cost and higher pre-discharge prealbumin levels. In another study examining the effect of early gastrostomy tube placement on stroke patients, it was found that early gastrostomy tube placement was associated with shorter LOS and higher odds of home or acute rehabilitation discharge disposition. In a retrospective study on intracerebral hemorrhage and subarachnoid hemorrhage patients, it was found that tracheostomy was associated with ICU LOS with almost a 10-day difference if tracheostomy is placed before 7 days or after 14 days. They also found a 6- day difference in overall length of stay between those who had the gastrostomy tubes placed before 7 days or after 14 days. Importantly they saw that the timing of tracheostomy and gastrostomy placement was not associated with mortality. In practice, usual care favors delayed gastrostomy due to availability of imaging resources, proceduralist coordination, and provider preference. Bedside PEG requires the availability of specialized mobile endoscopic equipment and physicians trained in upper endoscopy. In a retrospective study of TSG, among the most common reason for procedural delays were coordination with GI service for performance of PEG. Further, mobile endoscopes are expensive and uncommon across the healthcare system, thus preventing PEG from practical generalizability as an early gastrostomy technique. TSG has been performed using standard PDT and PUG. Because PUG utilizes point-of-care ultrasound (POCUS) technology readily available at the bedside it is a generalizable method for early gastrostomy. Finally, direct comparative evidence to support guidelines for TSG over TDG do not exist. In the absence of clear guidelines, provider preference permits delayed gastrostomy decisions.There is currently no prospective study analyzing the effect of tracheostomy with bedside simultaneous gastrostomy versus tracheostomy with delayed gastrostomy placement (TSG versus TDG) on the outcomes of neurocritically-ill patients. To analyze the effect on patient outcomes of early intervention (TSG versus TDG), a pragmatic randomized clinical trial is needed. The investigators will study TSG via concomitant PDT and PUG procedures, while TDG will occur per usual care. This study is a prospective randomized open-label blinded endpoint study to assess the effect of tracheostomy with bedside simultaneous gastrostomy (TSG) versus the usual care of tracheostomy with delayed gastrostomy (TDG) placement on outcomes of neurocritically-ill patients.

Being tested
Timing of placement
Medical subject headings
Stroke, Neuromuscular Diseases, Status Epilepticus, Coma, Cerebrovascular Disorders, Spinal Cord Injuries, Trauma, Nervous System

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Timing of placementOther

    Simultaneous placement of tracheostomy and gastrostomy

Study groups in NCT04758052
Study groupRoleWhat they receive
simultaneous tracheostomy with gastrostomy (TSG)ExperimentalThis arm include the patients assigned to placement of gastrostomy immediately after tracheostomy.
Receives: Other: Timing of placement
non-simultaneous or delayed approach tracheostomy and gastrostomy (TDG)No interventionThis arm include the patients who proceed with "usual care" placement of tracheostomy and gastrostomy as per Neurocritical care Unit service standard.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ICU length of stay

    total number of midnights a patient is in the ICU for the duration of their hospital stay

    Measured: during hospital stay, assessed up to 10 days

Secondary outcomes (10)
  1. hospital length of stay

    total number of midnights a patients is in the hospital for the encounter that the patient

    Measured: during hospital stay, assessed up to 10 days

  2. nutritional metrics

    pre-albumin, albumin, caloric requirements met

    Measured: up to 14 days before the procedure and up to 14-days before discharge

  3. procedural analgo-sedation used

    total dosage of analgo-sedation used

    Measured: intraprocedure

  4. all-cause mortality

    proportion of patients who expired due to all-causes

    Measured: during hospital stay, assessed up to 10 days

  5. swallow function return

    presence, and time to minimal nectar thickened diet is allowed

    Measured: during hospital stay, assessed up to 10 days

  6. discharge disposition

    discharge location (acute rehabilitation, home, LTAC, nursing home, transferred, expired)

    Measured: during hospital stay, assessed up to 10 days

  7. Functional outcome

    Glasgow Outcome Scale Extended, Minimum score =1, Maximum score= 8, lower score is worse

    Measured: at discharge, assessed up to 6-months

  8. total analgo-sedation dose and duration in the ICU

    total analgo-sedation dosages (infusion and boluses)

    Measured: within ICU-stay, assessed up to 10 days

  9. proportion of ventilator acquired pneumonia before and after procedures

    according to updated CDC definition (https://www.cdc.gov/nhsn/PDFs/pscManual/6pscVAPcurrent.pdf)

    Measured: within ICU stay, assessed up to 10-days

  10. overall ICU and hospital cost

    total ICU cost estimated by LOS and severity-derived-diagnosis-related groups [DRG] multiplicator of each patient (Bösel et al., 2013) and total hospital cost at discharge

    Measured: within in-hospital stay, assessed up to 10-days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Feb 2021
  2. Study start31 Mar 2021
  3. Primary completionJan 2022 (estimated)
  4. Study completionAug 2022 (estimated)

Why it stopped: Principal Investigator change in institution

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
single-center prospective randomized open-label blinded endpoint proof-of-concept study to assess the effect of TSG versus usual care TDG placement on outcomes among neurocritically-ill patients.
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04758052
Sponsor's protocol ID
2020V0278
Acronym
BEGASTON
Status last verified
Jun 2021
First submitted
4 Feb 2021
Last updated
9 Jun 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Timing of placement in people with Stroke, Acute and TBI, run by University of Mississippi Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 9 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ICU length of stay (time frame: during hospital stay, assessed up to 10 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in